Inclusion Criteria:

• Recurrent malignant glioma with radiographic progression
• No more than three prior therapies.
• Male or female patients >=18 years old
• KPS >=60.
• Ability to provide written informed consent or consent obtained from responsible healthcare proxy.
• Contrast-enhanced MRI within 2 weeks of enrollment.
• Life expectancy >= 8 weeks
• Neutrophils >1500/mm3
• Platelets > 100,000/mm3L
• Hemoglobin >=9 g/dL
• AST/SGOT and ALT/SGPT <= 2.5 x upper limit of normal (ULN) or < 5.0 x ULN if the transaminase elevation is due to disease involvement
• Serum bilirubin <= 1.5 x ULN
• Serum creatinine <= 1.5 x ULN or 24-hour creatinine clearance >= 50 ml/min
• Total serum calcium or ionized calcium WNL
• Serum potassium WNL
• Serum sodium WNL
• Serum albumin >= LLN or 3g/dl
• Elevated Alkaline Phosphatase due to bone metastasis can be enrolled
• Baseline MUGA or ECHO must demonstrate LVEF >= the LLN
• TSH and free T4 WNL (patients may be on thyroid hormone replacement)
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method during the study and for 3 months after last study drug administration.
• No concurrent antitumor therapy.
• No enzyme-inducing antiepileptic drugs.
• No significant comorbidities
• Patients must have recovered from toxic effects of prior therapy.

Exclusion criteria

• Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
• Valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
• Impaired cardiac function including:
• Screening ECG with a QTc > 450 msec
• Congenital long QT syndrome
• History of sustained ventricular tachycardia
• History of ventricular fibrillation or torsades de pointes
• Bradycardia < 50 beats per minute. Patients with a pacemaker and heart rate > = 50 beats per minute are eligible.
• Myocardial infarction or unstable angina within 6 months
• Congestive heart failure (NYHA class III or IV)
• RBBB and LAH (bifascicular block)
• Uncontrolled hypertension
• Concomitant use of drugs with a risk of causing torsades de pointes Concomitant use of CYP3A4 inhibitors
• Patients with unresolved diarrhea
• Impairment of gastrointestinal (GI) function or GI disease that may significantly alter absorption of LBH589
• Concurrent severe and/or uncontrolled medical conditions
• Chemotherapy, any investigational drug or major surgery < 4 weeks prior to starting study drug or have not recovered from side effects of such therapy.
• Concomitant use of any anti-cancer therapy or radiation therapy.
• Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method.
• Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom
• History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
• Known human immunodeficiency virus (HIV) or hepatitis C positivity
• Significant history of non-compliance to medical regimens or inability to grant a reliable informed consent
• More than three prior therapies
• Hepatic or renal diseases or any diseases that will obscure toxicity or alter drug metabolism
• Known active malignancies
• Active infection requiring iv antibiotics
• Systemic anticoagulants
• Enzyme-inducing antiepileptic drugs